Related by context. All words. (Click for frequent words.) 81 pharmacokinetic 79 pharmacodynamics 77 pharmacokinetic profile 76 tolerability 74 pharmacokinetics PK 73 safety tolerability pharmacokinetics 72 safety tolerability 71 pharmacodynamic 69 pharmacodynamic profile 69 safety tolerability pharmacokinetic 68 pharmacokinetics pharmacodynamics 67 pharmacokinetic profiles 67 immunogenicity 66 pharmacodynamic PD 66 pharmacodynamic effects 66 ascending doses 66 tolerability profile 66 pharmacokinetic parameters 65 bioavailability 65 pharmacokinetic studies 65 pharmacokinetic properties 65 tolerability pharmacokinetics 64 antiviral activity 64 single ascending dose 64 pharmacokinetic PK 64 efficacy 64 analgesic efficacy 64 dose escalation study 63 Phase Ib 63 tolerated dose MTD 63 pharmacodynamics PD 63 dosing regimens 63 double blind placebo 63 Pharmacokinetic 63 biodistribution 62 ascending dose 62 pharmacokinetic PK profile 62 anti leukemic 62 placebo controlled 61 pharmacodynamic properties 61 oral bioavailability 61 pharmacokinetic characteristics 61 Pharmacokinetics 61 active comparator 60 plasma concentrations 60 Phase 1a 60 subcutaneously administered 60 Phase IIa 60 antiviral efficacy 60 Phase Ib clinical 60 Phase 2b study 60 preclinical efficacy 60 pharmacokinetic pharmacodynamic 60 Phase 1b trial 60 multiple ascending dose 60 Phase 1b 60 antitumor activity 60 efficacy tolerability 60 administered subcutaneously 60 CK # 60 Pharmacokinetics PK 59 dose limiting toxicities 59 dose escalation trial 59 Phase Ia 59 favorable pharmacokinetic profile 59 Phase IIa trial 59 blind placebo controlled 59 orally administered 59 PF # [001] 59 plasma pharmacokinetics 59 rHuPH# 59 dose escalation 59 polymerase inhibitor 59 pharmacodynamic markers 59 teduglutide 59 ORMD 59 subcutaneous SC 59 tolerability profiles 58 oral dosing 58 Phase 2a clinical 58 SCH # 58 decitabine 58 PXD# 58 dosage regimens 58 phase Ib 58 maximally tolerated dose 58 PRTX 58 PEG Interferon lambda 58 Phase 1b clinical 58 melphalan prednisone 58 pharmacodynamic parameters 58 dose cohorts 58 teriflunomide 58 varespladib 58 vivo 58 randomized double 58 intermittent dosing 58 dosing 58 orally bioavailable 57 Cmax 57 PSN# [002] 57 Imprime PGG 57 RDEA# 57 double blinded placebo 57 administered orally 57 Phase IIa clinical 57 preclinical studies 57 active metabolite 57 coadministration 57 dosing schedules 57 multicenter Phase II 57 viral kinetics 57 oral prodrug 57 Omacetaxine mepesuccinate 57 LEP ETU 57 label dose escalation 57 CYT# 57 dose regimens 57 Phase Ib clinical trials 57 Secondary endpoints 57 nonclinical studies 57 systemically administered 57 posaconazole 57 preclinical pharmacokinetic 57 INCB# [001] 57 pharmacodynamic profiles 57 dose proportionality 57 pharmacokinetic PK study 57 dose dose escalation 57 blind randomized placebo 57 tanespimycin 57 nab paclitaxel 57 PS# [001] 57 Sym# 57 GRN#L 56 fluticasone furoate 56 mg dose 56 cannabinor 56 Phase 2b trial 56 randomized placebo controlled 56 pomalidomide 56 masked placebo controlled 56 viral kinetic 56 rFIXFc 56 liposomal formulation 56 Phase 2b clinical 56 Phase Ib study 56 nucleoside analog 56 PK PD 56 CANCIDAS 56 etoposide 56 fosbretabulin 56 dosed orally 56 bendamustine 56 Phase 2a trial 56 Antiviral Activity 56 elotuzumab 56 vitro cytotoxicity 56 pharmacokinetic interactions 56 ISIS # 56 #mg dose [001] 56 glucose lowering 56 DermaVir Patch 56 prucalopride 56 subcutaneous formulation 56 Azedra 56 dose proportional pharmacokinetics 56 RG# [001] 56 ritonavir boosted 56 acting muscarinic antagonist 56 inhibitor RG# 56 docetaxel 56 Pharmacokinetic PK 56 Secondary endpoints include 56 immunomodulator 56 IMC A# 56 nucleotide analog 56 monotherapy 56 intravesical 56 torezolid phosphate 56 intravenously administered 56 APTIVUS r 56 GAMMAGARD 56 μg kg 56 azacitidine 55 rhGH 55 daunorubicin 55 non nucleoside 55 NGX# 55 dose escalation Phase 55 #mg QD [002] 55 PEG PAL 55 GFT# 55 Blinatumomab 55 phase IIb clinical 55 urocortin 2 55 JAK inhibitor 55 Tolerability 55 HGS ETR1 55 selective modulator 55 CRx 55 HGS ETR2 55 secondary efficacy endpoints 55 AEG# 55 intravenous dosing 55 pharmacodynamic endpoints 55 CLORETAZINE TM VNP#M 55 Phase Ib II 55 preclinically 55 Phase IIb clinical 55 prodrug 55 erythropoietic 55 blinded randomized placebo controlled 55 SRT# [003] 55 Triolex 55 CK # administered 55 pharmacological 55 vinorelbine 55 orally dosed 55 AAG geldanamycin analog 55 pharmacologic 55 CTA# 55 partial agonist 55 urate lowering 55 bronchodilation 55 KRN# 55 serum concentrations 55 Pharmacokinetic studies 55 antitumor 55 HGS# 55 sunitinib malate 55 nitazoxanide 55 receptor inhibitor 55 chlorambucil 55 imetelstat 55 ADAGIO study 55 renal function 55 investigational oral 55 RE SURGE 55 riociguat 55 tasimelteon 55 Interferon alpha 55 parathyroid hormone PTH 55 CG# [003] 55 blinded placebo controlled 55 #mg BID [003] 55 LEXIVA r 55 lanthanum carbonate 55 indibulin 55 glatiramer acetate 55 Phase 2b 55 FOSRENOL ® 54 zonisamide SR 54 optimal dosing 54 APTIVUS 54 systemic absorption 54 efficacy endpoints 54 desvenlafaxine succinate 54 galiximab 54 antitumor effect 54 PREZISTA r 54 PPAR gamma agonist 54 visilizumab 54 ARRY 54 CA4P 54 Kahalalide F 54 davunetide intranasal AL 54 PI3K inhibitor 54 Traficet EN 54 randomized multicenter 54 MGCD# [002] 54 metabolic parameters 54 dosing regimen 54 Preclinical studies 54 mTOR inhibitors 54 nonrandomized 54 Androxal TM 54 Teriflunomide 54 belinostat 54 Aclidinium 54 novel VDA molecule 54 RSD# oral 54 IAP inhibitor 54 arbaclofen 54 favorable pharmacokinetic 54 vidofludimus 54 Chemophase 54 Cloretazine 54 dose regimen 54 Phase #/#a 54 BAL# [002] 54 Phase III clinical 54 Inhalation Solution 54 amprenavir 54 multicenter randomized placebo controlled 54 Archexin 54 antiviral potency 54 transgene expression 54 bosentan 54 active moiety 54 beta2 agonist 54 μg dose 54 Posiphen 54 antithrombotic 54 Xanafide 54 cyclophilin inhibitor 54 TAXUS VI 54 isoproterenol 54 DP b# 54 TRV# [001] 54 #beta estradiol 54 Carfilzomib 54 clinical trial 54 gemcitabine Gemzar ® 54 prasterone 54 oral formulation 54 vicriviroc 54 radiation dosimetry 54 Primary endpoints 54 immunomodulatory therapy 54 placebo controlled randomized 54 ganetespib 54 L PPDS 54 IFN alpha 54 apremilast 54 phase IIa clinical 54 Pegasys ® 54 mg BID 54 anti resorptive 54 histone deacetylase inhibitor 54 QD dosing 54 celgosivir 54 peripheral blood mononuclear 54 DLTs 54 peginterferon alpha 2a 54 MGd 54 Panzem R NCD 54 limiting toxicity DLT 54 glycemia 54 AKT inhibitor 53 TELINTRA 53 TMC# C# 53 pitavastatin 53 omecamtiv mecarbil 53 ENMD # 53 eculizumab 53 demonstrated antitumor activity 53 MAP# 53 oral diclofenac 53 Preclinical studies suggest 53 tecarfarin 53 multicenter randomized 53 candesartan cilexetil 53 linear pharmacokinetics 53 investigational drug 53 Phase IIb 53 anticancer agent 53 safety tolerability pharmacodynamics 53 PRT# 53 Luteinizing Hormone Releasing Hormone 53 long acting muscarinic 53 Omacetaxine 53 bioequivalence 53 plasma uric acid 53 Marqibo 53 DAVANAT 53 obatoclax 53 Tolvaptan 53 cytotoxicity 53 randomized #:# 53 oral rivaroxaban 53 IMGN# 53 busulfan 53 blind randomized 53 MIRCERA 53 Phase 2a 53 TACI Ig 53 AEGR 53 mecamylamine 53 gastrointestinal motility 53 placebo controlled clinical 53 low dose cytarabine 53 depsipeptide 53 insulin detemir 53 IDX# 53 gemcitabine 53 NEUGENE antisense 53 xenograft models 53 CaPre TM 53 synthetic siRNA 53 Symadex 53 Ostarine 53 diabetic neuropathic pain 53 eniluracil 53 NOX E# 53 phase IIb 53 retaspimycin 53 temozolomide 53 Elacytarabine 53 pertuzumab 53 muscarinic 53 secondary endpoint 53 huN# DM1 53 6R BH4 53 LY# [002] 53 antidepressant efficacy 53 piperacillin tazobactam 53 5 FU 53 effector function 53 atazanavir ritonavir 53 interferon alfa 53 phase 2a 53 Phase #b/#a 53 subcutaneous dose 53 MEK inhibitor 53 CDK inhibitor 53 antiretroviral naive 53 phase IIa 53 Pharmacokinetic parameters 53 platelet inhibitor 53 PMX # 53 HDAC inhibitor 53 sunitinib 53 BAY #-# 53 pharmacokinetic equivalence 53 clotrimazole 53 placebo controlled Phase 53 randomized 53 Iloperidone 53 uric acid lowering 53 ritonavir boosting 53 multicenter randomized double 53 reactogenicity 53 CTCE 53 investigational compound 53 enzastaurin 53 KSP inhibitor 53 pivotal Phase 53 mapatumumab 53 docetaxel Taxotere 53 multicenter Phase III 53 label multicenter 53 achieved statistical significance 53 CCR5 antagonist 53 investigational hepatitis C 53 dexamethasone Decadron 53 Debio 53 selective agonist 53 topotecan 53 irbesartan 53 antitumor effects 53 S/GSK# 53 CoFactor 53 HMG CoA reductase inhibitors 53 tiotropium 53 controlled multicenter 53 glycopyrrolate 53 oral deforolimus 53 liposome injection 53 elvitegravir 53 functional dyspepsia 53 microsomal 53 vorinostat 53 immunomodulatory effects 53 ALB # 53 mg kg BID 53 Anticalins ® 53 paclitaxel poliglumex 53 edoxaban 53 ISENTRESS 53 serotonin norepinephrine reuptake inhibitor 53 thymalfasin 53 murine 53 selectively inhibits 53 granisetron 53 mg doses 53 inhibitory effects 53 humanized anti 53 OMP #M# 53 Phase #b/#a trial 53 TMC# [002] 53 Anticalins 53 Vidaza azacitidine 53 BMS# 53 anti proliferative 53 placebo controlled dose escalation 53 EZN 53 efavirenz EFV 53 cynomolgus monkeys 53 dosing cohorts 53 peripherally acting 53 TMC# [001] 53 stated Michelle Berrey 53 double blinded randomized 53 2 methoxyestradiol 53 sorafenib Nexavar ® 53 IFN β 53 RezularTM 53 sorafenib Nexavar 53 CIMZIA TM certolizumab pegol 53 fosamprenavir 53 cytotoxic 53 vivo efficacy 53 demonstrated statistically significant 53 R#/MEM # 53 Phase 1a clinical 53 small molecule 53 primary endpoint 53 Phase 2b clinical trials 53 LT NS# 53 CR# vcMMAE 52 generation purine nucleoside 52 antidiabetic 52 sitagliptin 52 NP2 Enkephalin 52 Exelixis compounds 52 oral antiviral 52 bevirimat 52 Toxicities 52 dopamine transporter 52 RH1 52 AZILECT R 52 estramustine 52 anti amnesic 52 Bioavailability 52 synthetic retinoid 52 insulin degludec 52 peg IFN 52 rNAPc2 52 Phase IIB 52 RE LY ® 52 trodusquemine 52 FOSRENOL R 52 Dacogen injection 52 R baclofen 52 dexpramipexole 52 VA# [002] 52 racemic 52 evaluating REVLIMID 52 NOXAFIL Oral Suspension 52 Phase IIA 52 resolvin 52 investigational protease inhibitor 52 favorable tolerability 52 placebo controlled studies 52 Dual Opioid 52 vitro experiments 52 GLYX 52 preclinical 52 REVLIMID lenalidomide 52 USL# 52 GAMMAGARD LIQUID 52 TNFalpha 52 plus ribavirin 52 Elvitegravir 52 CIMZIA TM 52 prospectively defined 52 topically administered 52 GLP toxicology studies 52 delafloxacin 52 Bezielle 52 alvespimycin 52 dose cohort 52 AzaSite Plus 52 receptor antagonist 52 uricase 52 dopamine D2 52 GHRH 52 novel histone deacetylase 52 ziprasidone 52 Phase IIb trial 52 VAPRISOL 52 DuraSite 52 PEGPH# 52 neratinib 52 liposomal doxorubicin 52 adalimumab 52 abacavir lamivudine 52 ZYBRESTAT fosbretabulin 52 Cloretazine R VNP#M 52 cytoprotective 52 synthetic peptide 52 AQ4N 52 vapreotide acetate 52 plus prednisone 52 5 HT6 receptor 52 topical formulation 52 5 HT2A 52 antitumour activity 52 lenalidomide dexamethasone 52 Annexin V 52 mg/m2/day 52 LEXIVA 52 receptor antagonists 52 Amrubicin 52 ug kg 52 MGCD# [001] 52 randomized Phase III 52 p# biomarkers 52 systemic antifungal 52 telaprevir dosing 52 placebo controlled Phase III 52 AZD# 52 tacrolimus 52 diarrhea predominant irritable 52 retinoid 52 multicentre randomized 52 lispro 52 radiolabeled 52 Prodarsan ® 52 Phase IIa trials 52 protease inhibitor 52 zileuton 52 selective antagonist 52 selegiline 52 diabetic gastroparesis 52 multicenter 52 sulodexide 52 dyskinesia PD LID 52 erlotinib Tarceva ® 52 pramlintide 52 intravesical instillation 52 dose escalation clinical 52 novel prodrug 52 tacrolimus ointment 52 clevidipine 52 subcutaneous dosing 52 kinase inhibition 52 PYY 52 Synavive 52 neuroprotective properties 52 Initiated Phase 52 Darinaparsin 52 solithromycin 52 ACTEMRA TM 52 prospective observational 52 Hyphanox 52 mRNA expression 52 rFVIIIFc 52 nelfinavir 52 mGluR5 NAM 52 voreloxin 52 carboplatin 52 budesonide foam 52 LHRH antagonists 52 Apoptone 52 Etoposide 52 Immunogenicity 52 telaprevir dosed 52 plasma lipid 52 secondary endpoints 52 EGFR HER2 52 Liposomal 52 MTP inhibitor 52 PEG SN# 52 pivotal Phase III 52 hyperphenylalaninemia HPA due 52 PRX# 52 fostamatinib 52 ANA# 52 chemotherapeutic drug 52 lipid 52 seliciclib 52 thorough QT 52 dyslipidaemia 52 docetaxel Taxotere R 52 multicenter Phase 52 mertansine 52 darunavir ritonavir 52 pramlintide metreleptin combination 52 LB# [003] 52 peak plasma concentrations 52 MP4OX 52 clinical endpoints 52 bavituximab 52 RSD# 52 tipranavir 52 mcg dose 52 pegylated 52 octreotide acetate 52 tipranavir r 52 guanfacine extended release 52 INC# 52 docetaxel chemotherapy 52 Tyrima 52 alpha 2a 52 eszopiclone 52 protease inhibitor PI 52 immunological 52 AST ALT 52 dosing cohort 52 daily subcutaneous injections 52 genotypic 52 latrepirdine 52 postprandial glycemia 52 dacarbazine 52 peginesatide 52 MEK inhibitors 52 secondary efficacy endpoint 52 Fx #A 52 alkylating agent 52 cytochrome P# #A# 52 ceftazidime 52 tirofiban 52 insulin lispro 52 HMG CoA reductase inhibitor 52 systemic bioavailability 52 serum leptin 52 LIALDA 52 FOLOTYN ® 52 transfected 52 ISTODAX 52 postmenopausal osteoporotic women 52 cilengitide 52 pafuramidine 52 BMS # 52 Bortezomib 52 AVE# 52 lipid parameters 52 omega interferon 52 kinase inhibitor 52 dyslipidemia 52 mg kg dose 52 anti angiogenic 52 aprepitant 52 INCB# [002] 51 pegylated liposomal doxorubicin 51 itraconazole 51 ancrod 51 glucocorticoid 51 prokinetic agent 51 cobicistat 51 atypical antipsychotic 51 axitinib 51 ALN TTR# 51 Prograf ® 51 LEVADEX 51 HCV polymerase inhibitor 51 potency selectivity 51 liposome formulation 51 placebo controlled clinical trials 51 plasma renin activity 51 subcutaneous doses 51 bile acid sequestrant 51 nanopharmaceutical 51 Secondary endpoints included 51 potent antiviral 51 interferon gamma 1b 51 highly selective inhibitor 51 dosing interval 51 FTY# 51 relapsed MM 51 relapsing multiple sclerosis 51 Neuradiab 51 RE LY trial 51 EOquin 51 PEGylated interferon beta 1a 51 torsemide ER 51 opioid mediated 51 APD# 51 Voreloxin 51 ZYBRESTAT 51 Phase III placebo controlled 51 hemostatic efficacy 51 peginterferon alfa 2b 51 IFN beta 51 gemcitabine Gemzar 51 #mg/m# [002] 51 Efficacy 51 HspE7 51 Navelbine 51 NPH insulin 51 PHX# 51 Amigal 51 antitumor efficacy 51 etanercept 51 imatinib resistant 51 immunomodulatory 51 selective inhibitor 51 #HT#A 51 anticancer activity 51 genotypic resistance 51 subchronic 51 TRO# 51 PRX # 51 EVIZON 51 5 HT1A receptor 51 astemizole 51 LCP AtorFen 51 randomized Phase 2b 51 Phase IIb clinical trials 51 JAK2 inhibitors 51 ESBA# 51 Phase IIIb clinical 51 CCX# 51 surrogate endpoint 51 LY# [003] 51 intravitreal injection 51 serum cortisol 51 dosing frequency 51 RG# ITMN 51 mg QD 51 5 HT2C receptor 51 sirolimus 51 Tamibarotene 51 Sapacitabine 51 immune modulating 51 Interferon beta 1a 51 NN# [001] 51 otelixizumab 51 GLP1 agonist 51 Anidulafungin 51 Akt activation 51 plasma kallikrein 51 bortezomib Velcade 51 Telintra 51 virologic response 51 randomized blinded 51 sapacitabine 51 alfa 2a 51 idarubicin 51 neuroprotective effects 51 octreotide 51 continuous intravenous infusion 51 direct thrombin inhibitors 51 lintuzumab 51 PEG IFN 51 DCCR 51 metaglidasen 51 latanoprost 51 Zenvia ™ 51 REG2 51 intranasal delivery 51 serum LDL cholesterol 51 beclomethasone dipropionate 51 ara C 51 mitoxantrone 51 BNC# 51 dacetuzumab 51 TG# [003] 51 azacytidine 51 osmolality 51 HIV RNA 51 DU #b 51 neurologic progression 51 immunological responses 51 HCV protease 51 GMX# 51 Ophena TM 51 antineoplastic 51 Initiate Phase 51 Panzem R 51 incretin 51 PDE4 inhibitor 51 Phase 2b randomized 51 alagebrium 51 Perifosine 51 IFN α 51 tipifarnib 51 XP# Transported Prodrug 51 caspofungin 51 randomized Phase 51 HDACi 51 MORAb 51 guanfacine 51 pathophysiological effects 51 retapamulin 51 NATRECOR ® 51 AEZS 51 metreleptin 51 pharmacologically active 51 Doxil ® 51 TAXUS Stent 51 mg TID 51 cytostatic 51 limiting toxicity 51 composite endpoint 51 GSK# [001] 51 cationic lipid 51 factor Xa inhibitor 51 hour bronchodilation 51 docetaxel Taxotere ® 51 vandetanib 51 Spheramine 51 Vilazodone 51 Belerofon 51 MGN# 51 phase IIb study 51 Tasimelteon 51 Zybrestat 51 DPP4 51 bupropion SR 51 CardioPET 51 lopinavir r 51 serum lipid 51 primary hypercholesterolemia 51 APPRAISE 51 capsule formulation 51 erlotinib 51 oral antidiabetic 51 mg/m2 dose 51 CEQ# 51 sitaxsentan 51 enfuvirtide 51 potentially hepatotoxic 51 5 HT2A receptor 51 CBLB# 51 small molecule chemotherapeutic 51 prostanoid 51 mixed hyperlipidemia 51 antiangiogenic therapy 51 label multicenter Phase 51 Dasatinib 51 Vidofludimus 51 bezafibrate 51 alvimopan 51 cytarabine 51 AP# [003] 51 mg kg 51 antifolates 51 plasma kallikrein inhibitor 51 palifosfamide 51 XmAb# 51 preclinical pharmacology 51 Enhanze Technology 51 intramuscular 51 serum PTH 51 doxorubicin cyclophosphamide 51 flavopiridol 51 Actilon 51 D aspartate NMDA receptor 51 preclinical models 51 Lp PLA 2 51 polymerase inhibitors 51 Pharmacodynamic 51 #mg/m# [001] 51 crizotinib PF # 51 4mg/kg 51 selective inhibition 51 heavily pretreated 51 CLARITY study 51 Melphalan 51 aripiprazole 51 nucleoside 51 alemtuzumab MS 51 somatostatin analogue 51 intramuscularly 51 pegylated interferon 51 registrational 51 oral dosing regimen 51 microtubule inhibitor 51 LATUDA 51 tezampanel 51 vitro studies 51 NXL# 51 clinical pharmacology studies 51 Alocrest 51 MBP# [001] 51 evaluating tivozanib 51 Phase IIIb 51 Zoraxel 51 randomized multicenter trial 51 mitomycin 51 budesonide 51 peptidomimetic 51 toxicity 51 antiarrhythmic 51 nucleoside reverse transcriptase inhibitor 51 QTc prolongation 51 8mg/kg 51 Zysolin TM 51 lomitapide 51 TRIOLEX 51 HDAC Inhibitor 51 Laquinimod 51 HIF 1a 51 bicifadine 51 HCV SPRINT 51 mcg kg 51 Adalimumab 51 systemic RNAi therapeutic 51 pyridostigmine 51 velafermin 51 Plicera 51 receptor agonists 51 huC# DM4 51 mouse xenograft models 51 REOLYSIN ® 51 VELCADE melphalan 51 angiotensin receptor blocker ARB 51 Raltegravir 51 Natalizumab 51 PREOS 51 rosuvastatin Crestor 51 ibandronate 51 topical formulations 51 carboplatin paclitaxel 51 elastase 51 timepoints